AnaptysBio Inc (NASDAQ:ANAB) stock plunged -0.53% and closed at 99.24 on Monday. The stock opened the session at $100.15 and touched its highest price point at $100.97. Its recent trading capacity is 410,085 shares versus to its average trading volume of 444956 shares. The company’s stock’s lowest price point for the session stood at $98.19.ANAB traded as low as $ 34.44 in the past 52 weeks, and shares hit its peak level to $134.
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, recently reported the closing of its underwritten public offering of 2,530,000 shares of its common stock at a public offering price of $94.46 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 330,000 shares of common stock. Gross proceeds to AnaptysBio from the offering are expected to be approximately $239.0 million, before deducting underwriting discounts and commissions and offering expenses.
Credit Suisse, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Cantor, Guggenheim Securities and Wedbush PacGrow acted as co-managers.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.